The best thing about this trial is the data. Other biotecs would be estatic to get real data from humans for the cost dxb was able to participate in this trial.
That being said I am leaning towards limited to nil benefit for covid.
fsgs is where it is at in the short to medium term with 700 showing some exciting results albeit in mice.
Ann: CLARITY 2.0 COVID-19 Study Concludes Recruitment, page-18
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35000 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 83901 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |